Sanofi to Pay $11.85 Million, Enter Corporate-integrity Agreement to Resolve Kickbacks Complaint
February 28 2020 - 5:25PM
Dow Jones News
By Maria Armental
Sanofi agreed to pay $11.85 million to resolve allegations that
sought to boost sales of multiple-sclerosis treatment Lemtrada by
using a charity to cover Medicare patients' out-of-pocket costs,
federal prosecutors said.
As part of the settlement, the French drug maker also entered
into a corporate-integrity agreement with the federal government, a
pact that typically requires companies to adhere to certain
business practices for several years.
"This resolution reflects the company's desire to put this
investigation behind it and to continue its focus on the needs of
patients," Sanofi said in a statement. "It does not constitute any
admission of guilt."
The case stems form a so-called whistleblower complaint filed in
Boston federal court.
Federal prosecutors accused Sanofi of funneling kickback
payments through The Assistance Fund, which had several funds,
including one for MS patients that covered the co-pays of some
Medicare patients who were prescribed Lemtrada.
TAF, federal prosecutors said, raised its maximum per-patient
grant allocation to $20,000, specifically to accommodate Lemtrada
patients.
Sanofi, the prosecutors said, worked with its third-party
reimbursement hub to identify Medicare patients who had been
prescribed Lemtrada but hadn't received infusions because they
couldn't afford the co-pays.
Sanofi made nine payments to TAF during 2015 and 2016, according
to prosecutors.
TAF, prosecutors said, didn't keep a wait list of patients.
Instead, when it received money, it would cover the costs of those
patients who had applied first.
Sanofi, prosecutors said, instructed its hub to quickly refer
the Lemtrada patients they had identified as soon as TAF opened its
fund to new patients.
"They rigged the system so those taking its drug Lemtrada gained
an unfair advantage over patients using other medications," said in
a statement Joseph R. Bonavolonta, special agent in charge of the
Federal Bureau of Investigation Boston division.
The whistleblower that filed the original claim, a limited
liability partnership formed by a former employee of Sanofi's
predecessor, Genzyme Corp., will receive about $2.7 million.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
February 28, 2020 17:10 ET (22:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024